title: [The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].
abstract: This consensus document was prepared by an expert panel of the Grupo de Estudio de Sida (GESIDA [Spanish AIDS Study Group]) and the Plan Nacional sobre el Sida (PNS [Spanish National AIDS Plan]). The document updates current guidelines on the treatment of tuberculosis (TB) in HIV-infected individuals contained in the guidelines on the treatment of opportunistic infections published by GESIDA and PNS in 2008. The document aims to facilitate the management and treatment of HIV-infected patients with TB in Spain, and includes specific sections and recommendations on the treatment of drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB, in this population. The consensus guidelines also make recommendations on the treatment of HIV-infected patients with TB in special situations, such as chronic liver disease, pregnancy, kidney failure, and transplantation. Recommendations are made on the timing and initial regimens of antiretroviral therapy in patients with TB, and on immune reconstitution syndrome in HIV-infected patients with TB who are receiving antiretroviral therapy. The document does not cover the diagnosis of TB, diagnosis/treatment of latent TB, or treatment of TB in children. The quality of the evidence was evaluated and the recommendations graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation Working Group.
authors.affiliation: Panel de Expertos del Grupo de estudio de Sida (GESIDA-SEIMC) y de la Secretaría del Plan Nacional sobre el Sida (SPNS); Unidad de Enfermedades Infecciosas, Hospital Universitario 1050 Reina Sofía-IMIBIC, Córdoba, España. Electronic address: ariveror@gmail.com.
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
authors.forename: Federico
authors.initials: F
authors.lastname: Pulido
authors.forename: Joan
authors.initials: J
authors.lastname: Caylá
authors.forename: José A
authors.initials: JA
authors.lastname: Iribarren
authors.forename: José M
authors.initials: JM
authors.lastname: Miró
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Inés
authors.initials: I
authors.lastname: Pérez-Camacho
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced / Q000628:therapy; D014376:Tuberculosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents
keywords: Anti-retroviral treatment; Antituberculous therapy; Extensively drug-resistant tuberculosis; Fármacos antituberculosos; Human immunodeficiency virus; Multidrug-resistant tuberculosis; Tratamiento antirretroviral; Tuberculosis; Tuberculosis con resistencia extendida; Tuberculosis multirresistente; Virus de la inmunodeficiencia humana